Pneumagen
Pneumagen is a clinical-stage biotech company developing Neumifil, a broad-spectrum antiviral intranasal drug for the prevention and treatment of viral respiratory tract infections (RTIs). Their mission is to develop innovative, life-saving, broad-spectrum antiviral therapies to prevent infections in at-risk patients, with a focus on respiratory diseases such as influenza, RSV, rhinovirus, and coronavirus including SARS-CoV-2. They leverage proprietary GlycoTarge™ technology to identify novel multivalent carbohydrate binding modules (mCBMs) for therapeutic development.
Industries
Nr. of Employees
small (1-50)
Products
Clinical-stage engineered multivalent glycan-binding biologic for intranasal prophylaxis
A protein-based multivalent glycan-binding therapeutic formulated as an intranasal spray developed for broad-spectrum prophylaxis and treatment of respiratory viral infections; shown in preclinical models to block viral engagement of host receptors and demonstrated clinical proof-of-concept in a human influenza challenge study.
Glycan-targeting discovery platform for therapeutics
A discovery platform that identifies and generates multivalent glycan-binding modules for development into therapeutics targeting infectious diseases.
Clinical-stage engineered multivalent glycan-binding biologic for intranasal prophylaxis
A protein-based multivalent glycan-binding therapeutic formulated as an intranasal spray developed for broad-spectrum prophylaxis and treatment of respiratory viral infections; shown in preclinical models to block viral engagement of host receptors and demonstrated clinical proof-of-concept in a human influenza challenge study.
Glycan-targeting discovery platform for therapeutics
A discovery platform that identifies and generates multivalent glycan-binding modules for development into therapeutics targeting infectious diseases.
Services
Clinical development of intranasal antiviral candidate
End-to-end clinical development of a protein-based intranasal antiviral through Phase 1 and Phase 2 clinical studies, including use of CHIM trials via CRO partnerships.
Clinical development of intranasal antiviral candidate
End-to-end clinical development of a protein-based intranasal antiviral through Phase 1 and Phase 2 clinical studies, including use of CHIM trials via CRO partnerships.
Expertise Areas
- Clinical trial management (including CHIM)
- Antiviral biologic development
- Glycobiology and glycan-targeting therapeutics
- Protein engineering and multivalent binder design
Key Technologies
- Multivalent carbohydrate-binding modules (mCBMs)
- Glycan-targeting host-directed antivirals
- Intranasal spray formulation and delivery
- Controlled Human Infection Model (CHIM)